open access

Online first
Clinical vignette
Published online: 2022-03-02
Get Citation

Sacubitril/valsartan improved microvascular endothelial function in a young patient with COVID-19-related mild left ventricular dysfunction

Marcin Hellmann1, Edyta Dąbrowska23, Marta Żarczyńska-Buchowiecka1, Marzena Romanowska-Kocejko1, Krzysztof Narkiewicz24, Marcin Gruchała3, Maria Dudziak1
DOI: 10.33963/KP.a2022.0063
·
Pubmed: 35235999
Affiliations
  1. Department of Cardiac Diagnostics, Medical University of Gdansk, Gdańsk, Poland
  2. Translational Medicine Centre, Medical University of Gdansk, Gdańsk, Poland
  3. 1st Department of Cardiology, Medical University of Gdansk, Gdańsk, Poland
  4. Department of Hypertension and Diabetology, Medical University, Gdańsk, Poland

open access

Online first
Clinical vignette
Published online: 2022-03-02

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Sacubitril/valsartan improved microvascular endothelial function in a young patient with COVID-19-related mild left ventricular dysfunction

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Online first

Article type

Clinical vignette

Published online

2022-03-02

Page views

108

Article views/downloads

84

DOI

10.33963/KP.a2022.0063

Pubmed

35235999

Authors

Marcin Hellmann
Edyta Dąbrowska
Marta Żarczyńska-Buchowiecka
Marzena Romanowska-Kocejko
Krzysztof Narkiewicz
Marcin Gruchała
Maria Dudziak

References (5)
  1. Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020; 41(32): 3038–3044.
  2. Hellmann M, Tarnawska M, Dudziak M, et al. Reproducibility of flow mediated skin fluorescence to assess microvascular function. Microvasc Res. 2017; 113: 60–64.
  3. Volpe M, Rubattu S, Battistoni A. ARNi: A Novel Approach to Counteract Cardiovascular Diseases. Int J Mol Sci. 2019; 20(9).
  4. Varga Z, Flammer A, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. The Lancet. 2020; 395(10234): 1417–1418.
  5. Gori M, D'Elia E, Senni M. Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives. Int J Cardiol. 2019; 281: 158–165.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl